Curadigm

Curadigm is an early-stage company focused on shifting the paradigm of therapeutic clearance, bioavailability, and efficacy to improve treatment outcomes for millions of patients. Curadigm was spun-off from Nanobiotix, a late-stage clinical company, in 2019 and maintains their commitment to cutting-edge therapeutic approaches. Curadigm has developed an industry-first nanotechnology designed to increase bioavailability and efficacy, while reducing off-target effects. Our product is administered intravenously just before the drug and “primes” the body to receive treatment by reducing rapid therapeutic clearance and hepatic toxicity. Curadigm’s priming technology is flexible and can be adapted to work with multiple therapeutic classes, including nanomedicines, nucleic acid therapeutics, small molecules, and gene editing technologies.